Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbHEuropean News
Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D
Tokyo, Munich and Basking Ridge, NJ – February 22, 2021 – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced Ken Takeshita,…
Daiichi Sankyo Creates New Business Unit to Unify Major Oncology Markets into One Streamlined Organization Dedicated to Patients with Cancer
Ken Keller Appointed as Head of the Oncology Business Unit Overseeing Global Oncology Strategy and U.S. and European Oncology Businesses
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
• Agreement represents second collaboration between Daiichi Sankyo and AstraZeneca for a Daiichi Sankyo DXd antibody drug conjugate (ADC)
•…
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugate Technology
Tokyo, Japan, Munich, Germany, Basking Ridge, NJ (November 4 / 5, 2019): Daiichi Sankyo Co., Ltd announced today that the company has filed a…
Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)
• Collaboration combines Daiichi Sankyo’s scientific and technological excellence with AstraZeneca’s global experience and resources in oncology to…
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
- Dr. Junichi Koga to become new global Head of Research & Development Unit and Co-Chair of the company's Global Executive Meeting of R&D (GEMRAD),…
Daiichi Sankyo Europe launches mycancertherapy.eu at ESMO 2018
New video-based website on cancer answers most frequently asked patient questions and simplifies medical jargon in 16 (EU & minority) different…
Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio
Intended for US and EU Medical Media Only
- Significant investment in antibody drug conjugate (ADC) manufacturing capabilities will improve research…
World Stroke Day 2016: Research reveals delayed diagnosis leaves atrial fibrillation patients at major stroke risk
• Atrial fibrillation (AF) increases the risk of a severe stroke [1] however almost half of patients are unaware of the risk [2]
• The AFfect survey…
Expert recommendations from the Future of Anticoagulation Report are to be undertaken to improve Atrial Fibrillation management
Management strategies in the new ESC Atrial Fibrillation Guidelines align with those identified in the Report to address the urgent public health…
